Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxue oral liquid for Alzheimer's disease with qi-blood deficiency syndrome
ChiCTR2400087425Phase 4Not yet recruiting
- Sponsor
- Huanggang Hospital of Traditional Chinese Medicine
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Yangxue Oral Liquid and donepezil in Alzheimer's disease (AD) (3 arms), sponsored by Huanggang Hospital of Traditional Chinese Medicine. Primary endpoints: Mechanism index at Day 90, DWI performance at Day 90 and 3 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
Yangxue Oral Liquiddonepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2400087425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087425.